サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1138297

A型肝炎ワクチンの世界市場-2022-2029

Global Hepatitis A Vaccine Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 190 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
A型肝炎ワクチンの世界市場-2022-2029
出版日: 2022年10月18日
発行: DataM Intelligence
ページ情報: 英文 190 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

予防に向けた政府の取り組みが増加

A型肝炎ワクチンは、増加するA型肝炎の症例を沈めるために使用されます。米国疾病管理センターによると、2018年に米国では合計12,474件のA型肝炎患者が報告され、未診断の症例があるため、同機関は年間の実際の報告数を24,900件と推定しています。このため、各国政府は、啓発、診断、治療、ワクチン接種への取り組みを強化しています。2022年4月21日現在、WHO欧州地域の11カ国とWHOアメリカ地域の1カ国から、少なくとも169件の原因不明の急性肝炎の症例が報告されています。WHOによると、衛生環境や衛生習慣が不十分な先進国では、10歳までに約90.0％の子どもがA型肝炎ウイルスに感染しているといいます。政府によるワクチン接種プログラムが、発展途上国におけるA型肝炎ワクチンの世界市場を後押ししています。

一方、A型肝炎に関する個人の認識不足は、予測期間中の世界市場の成長を抑制する主要因となることが予想されます。さらに、診断に対する住民の抵抗感も市場の成長を阻害しています。

当レポートでは、A型肝炎ワクチンの世界市場について、約48の市場データ表、43の図表、190ページにわたる情報を提供しています。

目次

第1章 調査手法と範囲

  • 調査手法
  • 市場の範囲

第2章 主な動向と発展

第3章 エグゼクティブサマリー

  • 製品タイプ別市場内訳
  • アプリケーション別市場内訳
  • 地域別市場内訳

第4章 市場の力学

  • 市場影響要因
    • 促進要因
    • 抑制要因
    • ビジネスチャンス
  • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • PEST分析
  • プライシング分析
  • リインバースメント分析
  • 法規制分析
  • アンメットニーズ
  • 特許動向

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み

第7章 製品タイプ別

  • 不活化ワクチン
  • 弱毒生ワクチン

第8章 用途別

  • 政府機関
  • 民間企業
  • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他の欧州地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第10章 競合情勢

  • 競合シナリオ
  • 競合他社の戦略分析
  • 市況/シェア分析
  • M&A（合併・買収）分析

第11章 企業プロファイル

  • GlaxoSmithKline
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Merck & Co., Inc.
  • Sanofi
  • Sinovac
  • Zhejiang Pukang
  • Changchun Institute of Biological
  • KM Biologics
  • IMBCA
  • ChangSheng
  • Convac

第12章 DataM

目次
Product Code: DMPH3111

Market Overview

Hepatitis A Vaccine Market size was valued at USD 876.9 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 3.5% over the forecast period 2022 to 2029.

Hepatitis A vaccine is a vaccine that prevents hepatitis A. The disease is a liver disorder caused by the hepatitis A virus leading from mild to severe illness. The Hepatitis A Virus (HAV) is transferred through either ingestion of contaminated food and water or direct contact with an infectious person. The disease has a propensity for cyclic reappearances, which occurs in epidemics globally. The antibodies introduced in response to the disease lasts through life and protect against recurrence of infection, the best way for which is through vaccination. It is given in two doses injected six months apart. The major factors propelling the growth of the Hepatitis A vaccine market are the increasing prevalence of hepatitis A globally, which leads to increasing concerns for vaccination. The rise in the number of Hepatitis A cases propels the national governments and healthcare organizations to introduce steps to increase awareness about the disease and manage vaccination drives in the risk-prone areas. Further continuous efforts by the market players to promote Hepatitis A vaccines drive the market growth.

Market Dynamics: Increasing government initiatives for prevention

Hepatitis A Vaccine is used to submerge the rising cases of Hepatitis A. As per the Center for Disease Control, in 2018, the U.S. reported a total of 12,474 hepatitis A cases, and the organization estimated the actual number of cases reported in the year to be 24,900 owing to the undiagnosed cases. This has propelled governments to increase their efforts for awareness, diagnosis, treatment, and vaccination. As of 21 April 2022, at least 169 cases of acute hepatitis of unknown origin have been reported from 11 countries in the WHO European Region and one country in the WHO Region of the Americas. According to the WHO, approximately 90.0% of children are infected with the hepatitis A virus before 10 years in developed countries with inadequate sanitary conditions and sanitation habits. Government vaccination programs are propelling the worldwide market for hepatitis A vaccines in developing countries.

On the other hand, lack of awareness concerning the Hepatitis A disease among individuals is a key factor expected to curtail the global market's growth over the forecast period. Moreover, resistance among the population for diagnosis also obstructs market growth.

Market Segmentation: Inactivated vaccine segment is projected to be the dominant segment in the market during the forecast period

Inactivated vaccines dominated the global market in 2019, also it is expected to present considerable growth shortly. Inactivated Vaccines are safe and highly functional. A two-dose schedule is traditionally recommended, particularly for travelers at significant risk of contracting hepatitis A and immunocompromised individuals. However, with a single dosage, equivalent efficacy has been achieved in stable people. This is expected to propel segmental growth soon.

Based on application, government institutions held the dominant position in the global market during the forecast period. Patients depend on public healthcare facilities for diagnosis and proper vaccination of Hepatitis A, supporting the segment growth during the forecast period. Moreover, the surging government programs offering vaccination drives are expected to project a considerable CAGR during the forecast period.

Geographical Penetration: Asia-Pacific is expected to dominate the global Hepatitis A Vaccine market

Asia-Pacific held a dominant position in the global Hepatitis A Vaccine market in 2021. In Asia-Pacific, China is expected to represent considerable growth during the forecast period. As in China, the live attenuated Hepatitis A Vaccine is becoming a favorable element to tackle the disease. Moreover, Europe is expected to represent significant growth in terms of value during the forecast period. The easy availability of vaccines at a comparatively lower cost is expected to propel market growth across the region. The Hepatitis A Vaccine market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by government policies and programs, especially in India and China. Moreover, the rise in the pediatric population and increased awareness about vaccination results in increasing demand for Hepatitis A Vaccine in emerging economies, such as India and China, which is expected to augment Asia Pacific's growth Hepatitis A Vaccine market.

Competitive Landscape:

The Hepatitis A Vaccine market is highly competitive, owing to the presence of major market players. The key Hepatitis A Vaccine player contributing to the global market's growth include GlaxoSmithKline, Merck & Co. Inc., Sanofi, Sinovac, Zhejiang Pukang, Changchun Institute of Biological, KM Biologics, IMBCA, ChangSheng, Convac, among others. The major players are adopting new expansion strategies for global growth in the Hepatitis A Vaccine market.

COVID-19 Impact: Negative impact on the global Hepatitis A Vaccine market

The outbreak of COVID-19 has negatively impacted the growth of the Hepatitis A Vaccine market globally. The disruption in the supply chain has majorly impacted the growth of the market amidst the pandemic. The escalated focus on COVID-19 vaccine development, product type, and distribution has led to de-escalation in Hepatitis A vaccines. Therefore, the COVID-19 pandemic has hampered the market value of the Hepatitis A Vaccine market in 2021

The global Hepatitis A Vaccine market report would provide an access to approximately 48 market data tables, 43 figures and 190 pages

Table of Contents

Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Supply Chain analysis
  • 5.3. PEST Analysis
  • 5.4. Pricing Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs
  • 5.8. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Product Type Segment
    • 7.1.2. Market attractiveness index, By Product Type Segment
  • 7.2. Inactivated Vaccine*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Live Attenuated Vaccine

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Application Segment
    • 8.1.2. Market attractiveness index, By Application Segment
  • 8.2. Government Institution *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Private Sector
  • 8.4. Other

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key region-specific dynamics
    • 9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Rest of South America
  • 9.4. Europe
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. U.K.
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Italy
      • 9.4.5.6. Rest of Europe
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive scenario
  • 10.2. Competitor strategy analysis
  • 10.3. Market positioning/share analysis
  • 10.4. Mergers and acquisitions analysis

11. Company Profiles

  • 11.1. GlaxoSmithKline *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Merck & Co., Inc.
  • 11.3. Sanofi
  • 11.4. Sinovac
  • 11.5. Zhejiang Pukang
  • 11.6. Changchun Institute of Biological
  • 11.7. KM Biologics
  • 11.8. IMBCA
  • 11.9. ChangSheng
  • 11.10. Convac
  • List not Exhaustive*

12. DataM

  • 12.1. Appendix
  • 12.2. About us and services
  • 12.3. Contact us